Saudi FDA To Cut Drug Approval Time With Abridged Reviews
This article was originally published in SRA
Executive Summary
The Saudi Food and Drug Authority is planning to introduce a system of abridged regulatory reviews for drugs that could cut the approval timeline by around 40% and make it easier for companies to both bring their products to Saudi Arabia and produce them locally. In another move, the agency is creating a new department to assess benefit-risk profiles and a new risk assessment model.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.